UNSPSC 51361918: Phenobarbital

This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YQE403BP4D, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but generally known as phenobarbital, which bears US NIH Compound Identifier 4763. European Medicines Agency schedules Phenobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09770MIG.

UNSPSC 51361918 Phenobarbital is a Commodity code, but the recent state and local procurement activity tagged under it centers not on phenobarbital specifically but on broader pharmaceutical procurement — generic multi-source pharmaceuticals, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. State and local governments are using this code tier to solicit managed pharmacy benefit services, emergency medical supplies, and pharmaceutical supply chain arrangements rather than individual active pharmaceutical ingredients. Issuing bodies span state health and human services departments (Texas HHS Commission), state procurement offices administering cooperative purchasing vehicles (Minnesota Department of Administration through MMCAP), and county health departments (Seminole County, Florida). The work involves establishing framework agreements with manufacturers and wholesalers, managing distribution logistics to multiple facilities and jurisdictions, and compliance with FDA, DEA, and drug supply chain security regulations.

Recent activity shows geographic spread across Texas, Minnesota (with multi-state participation including Oregon), and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802), due March 26, 2026, sought manufacturers of generic pharmaceuticals and OTC products for distribution through three authorized wholesalers to state and local government facilities across participating states, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing structure, and 5 percent each on administrative fee format, EDI capability, and fee agreement. Seminole County, Florida issued an IFB (IFB60459723LAS) due July 26, 2023 (note: posted date June 30, 2026 appears inconsistent with the due date), soliciting annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to a county health facility. The Texas HHS Commission issued an RFI (HHS0017013) in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code shows active state-level and multi-state cooperative purchasing activity but limited representation from individual municipalities or school districts.